@article {de Freitas2020.12.30.20249060, author = {Raquel Falc{\~a}o de Freitas and Sofia Cardoso Torres and Jos{\'e} Pedro L. Nunes}, title = {Syncope and COVID-19 disease {\textendash} a systematic review}, elocation-id = {2020.12.30.20249060}, year = {2021}, doi = {10.1101/2020.12.30.20249060}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Syncope is not a common manifestation of COVID-19, but it may occur in this context and it can be the presenting symptom in some cases. Although several mechanisms may explain the pathophysiology behind COVID-19 related syncope, a valid relationship has not been established yet. In this systematic review, we aimed to examine the current incidence of syncope in COVID-19 patients and to explore different patterns observed in this setting.Methods A systematic review across PubMed, ISI Web of Knowledge and SCOPUS was performed, according to PRISMA guidelines, in order to identify all relevant articles regarding both COVID-19 and syncope.Results We identified 81 publications, of which 62 were excluded. The cumulative incidence of syncope and pre-syncope across the selected studies was 7.1\% (256/3584 patients). Unspecified syncope was the most common type (76.2\% of the reported episodes), followed by reflex syncope (18.1\% of the cases). Orthostatic hypotension was responsible for 3.6\% of the cases and syncope of presumable cardiac cause accounted for 2.0\%. Arterial hypertension was present in 64.7\% of the patients and either angiotensin receptor blockers or angiotensin converting enzyme inhibitors were used by 39.5\% of hypertensive patients with syncope.Conclusion Syncope, although not considered a typical symptom of the COVID-19 disease, can be associated with it, particularly in early stages. Different types of syncope were seen in this context, each with different implications requiring distinct approaches. A careful reevaluation of blood pressure whenever a patient develops COVID-19 is suggested, including reassessment of antihypertensive therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics committee approval is needed for systematic reviewsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData obtained from the published scientific literature}, URL = {https://www.medrxiv.org/content/early/2021/01/05/2020.12.30.20249060}, eprint = {https://www.medrxiv.org/content/early/2021/01/05/2020.12.30.20249060.full.pdf}, journal = {medRxiv} }